Clinical Trial Update: Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies [Phase 1]

View source ↗

Summary

Phase 1 dose-determining study evaluating EXS73565 in participants with relapsed or refractory B-cell malignancies; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Malignancies

Drugs mentioned

• EXS73565

Snippet

Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | Conditions: Relapsed or Refractory B-cell Malignancies | Phase 1 | Status: RECRUITING